Maule

Researchers are studying post-traumatic stress disorder PTSD and complex PTSD CPTSD, which includes additional symptoms affecting self-organization. This study evaluates the feasibility and acceptability of trauma-focused cognitive behavioral therapy for complex presentations TF-CBT-CP delivered via videoconference to adults diagnosed with PTSD or CPTSD in community mental health services and hospitals in the Maule Region, Chile. The study is a pilot with a mixed design involving 13 adults to prepare for a larger trial in this population. Participants will receive TF-CBT-CP therapy consisting of 16 weekly 60-minute sessions delivered by trained clinical psychologists using videoconference. The therapy includes assessment, psychoeducation, coping strategy development, behavioral activation, emotional regulation and interpersonal skills, exposure to traumatic memories, cognitive interventions, and relapse prevention. Sessions and assessments will take place in clinical settings equipped with the necessary technology to ensure privacy and connectivity. Participants will undergo initial and follow-up evaluations via videoconference using clinical interviews and questionnaires assessing PTSD, CPTSD, depression, anxiety, suicidal ideation, substance use, emotional regulation, and functioning. Satisfaction with the intervention and reasons for dropout will be monitored. Feasibility outcomes include recruitment, retention, and treatment completion rates, while secondary outcomes focus on symptom reduction and psychological well-being improvements. Qualitative interviews will explore participant acceptability after treatment completion, with total participation lasting about 20 weeks.

Researchers are evaluating the effectiveness and safety of paltusotine compared to a placebo in adults with carcinoid syndrome caused by well-differentiated neuroendocrine tumors. This Phase 3 study aims to continue assessing the safety, efficacy, and how the body processes paltusotine. Carcinoid syndrome symptoms include flushing and frequent bowel movements, and the study focuses on these symptoms in affected adults. Participants are randomly assigned to receive either paltusotine at a dose of 80 mg daily or a placebo. The study includes several phases a screening period of up to 11 weeks to determine eligibility, a 16-week double-blinded treatment period where neither participants nor researchers know who receives the drug or placebo, followed by a 104-week open-label extension where all participants can receive paltusotine. After treatment, there is a 4-week follow-up period. During the study, participants will record daily flushing episodes and bowel movements using a diary to help measure the treatment effects. Researchers will monitor safety and treatment response throughout all phases. The total participation time can last over two years, including the screening, treatment, extension, and follow-up periods. This long-term approach helps assess both immediate and extended effects of paltusotine.